Approval · Notice of Compliance 28202 · 2022
AMLODIPINE: Notice of Compliance 28202
Issued May 16, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28202
- Date
- May 16, 2022
- Company
- Sanis Health Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement Between Two Companies
- Canadian reference product
- NORVASC (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AMLODIPINE | 02478587 | Marketed |
| AMLODIPINE | 02331284 | Marketed |
| AMLODIPINE | 02331292 | Marketed |
Medicinal ingredients
- AMLODIPINE 2.5 MG per TAB
- AMLODIPINE 5 MG per TAB
- AMLODIPINE 10 MG per TAB